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Abstract
Background: Molecular targeted therapies have dramatically improved the prognosis of metastatic renal cell
carcinoma. However, patients in whom the treatment could initially be effective will experience disease
progression later.
Case presentation: A 74-year-old Japanese man who was diagnosed with renal cell carcinoma with no
evidence of metastasis presented to our hospital. He initially underwent radical nephrectomy, and subsequently the
disease metastasized to the lung. Sorafenib was started for the lung metastases 1 year after the operation. The dose of
sorafenib was reduced and temporarily discontinued because adverse events, including fatigue and cardiac infarction,
occurred. The patient has continued sorafenib monotherapy for over 10 years without disease progression and severe
adverse events.
Conclusions: We present a rare case of a patient with metastatic renal cell carcinoma who has survived for over 10
years while receiving sorafenib monotherapy.
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Background
Renal cell carcinoma (RCC) accounts for 3 % of adult
malignancies and 90 % of neoplasms arising from the
kidney [1]. Approximately 20–40 % of patients with ini-
tially localized disease who have had a nephrectomy will
go on to develop metastases [2]. Patients with metastatic
disease have a poor prognosis, with 5-year survival rates
being less than 10 % [2].
In recent years, targeted therapies have dramatically
improved the prognosis of patients with metastatic RCC
[3–6]. Some groups have demonstrated that there are
several prognostic factors for metastatic RCC other than
the Memorial Sloan Kettering Cancer Center (MSKCC)
risk classification system, including serum C-reactive
protein level, metastasis status, and tumor shrinkage
[7–10]. Previously, we reported that the duration of
first-line treatment with molecular targeted therapies
is the strongest prognostic factor in patients with
metastatic RCC [11]. In Japan, three types of tyrosine
kinase inhibitors (TKIs), such as sorafenib, sunitinib,
and pazopanib, and one type of mammalian target of
rapamycin are applicable for patients with metastatic
RCC as first-line molecular targeted therapy. However,
there have been few reports of survival for over 10
years following treatment with only one molecular
targeted agent. In this report, we present a case of a
patient with metastatic RCC who has survived for
over 10 years while receiving sorafenib monotherapy.
Case presentation
Our patient was a 74-year-old Japanese man who had
been diagnosed with a left renal mass and no evidence of
metastasis 11 years before presentation to our hospital.
Left radical nephrectomy was performed. The histology of
the renal tumor showed clear cell RCC, Fuhrman nuclear
grade 2, which was classified as pathological stage
T2bN0M0 according to TMN classification. Multiple
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pulmonary metastases were discovered 10 months after
surgery. The patient was stratified as intermediate risk ac-
cording to the MSKCC criteria. Although immunotherapy
(interleukin-2 plus interferon) was started, disease pro-
gression was observed on a follow-up computed tomo-
graphic (CT) scan 6 months later (Fig. 1a).
Therefore, the patient was included in a phase II clinical
trial and was started on treatment with oral sorafenib
(Nexavar®; Bayer HealthCare Pharmaceuticals, Whippany,
NJ, USA) 800 mg/day 16 months after surgery. Three
months after the initiation of sorafenib, a CT scan showed
19.3 % regression based on the Response Evaluation Cri-
teria in Solid Tumors. Then, after 1 year, 70.1 % regression
was observed (Fig. 1b). At this time, as grade 2 fatigue and
grade 1 aspiration pneumonia emerged, the dose was re-
duced to 400 mg/day. In addition, the patient twice had
acute myocardial infarctions, one 4 years and one 5 years
after initiation of sorafenib. Because general fatigue and
weakness occurred, sorafenib treatment was stopped 5.5
years after initiation.
Progression of pulmonary metastases was observed 8
months after sorafenib treatment was stopped (Fig. 1c).
Although we were reluctant to use a molecular targeted
agent, we decided to prescribe sorafenib according to
the strong wish of the patient. Treatment with sorafenib
was restarted at 200 mg/day. Because this dose was well-
tolerated without adverse events, sorafenib was increased
to 400 mg/day 5 months after had been restarted. The pa-
tient experienced grade 2 fatigue 7.5 years after initiation
of sorafenib. Therefore, the schedule was changed to 3
days of treatment and 1 day of rest. The patient has con-
tinued sorafenib on this schedule without disease progres-
sion or severe adverse events (Fig. 1d).
Discussion
With the introduction of molecular targeted therapy,
treatment of metastatic RCC has improved dramatically.
Currently, molecular targeted agents are considered a
standard first-line treatment for metastatic RCC. Sorafe-
nib is an oral, multitargeted TKI that targets prolifera-
tion and angiogenesis by inhibiting vascular endothelial
growth factor receptors 1–3, platelet-derived growth fac-
tor receptor (PDGFR)-β, and Raf kinase [3, 12, 13]. In
the TARGET study, the median progression-free survival
(PFS) and overall survival (OS) of patients treated with
sorafenib were 5.5 months and 17.8 months, respectively
[3]. Some reports on Japanese patients showed that PFS
ranged from 7.4 to 9 months [14, 15]. Although molecu-
lar targeted agents such as sorafenib significantly pro-
long survival of patients with metastatic RCC compared
with previous treatment, development of drug resistance
is inevitable. Patients in whom treatment is initially ef-
fective will eventually experience disease progression. In
our patient, cancer control has been achieved for over
10 years with sorafenib monotherapy. Because of adverse
events such as fatigue and acute myocardial infarction,
the patient temporarily discontinued the treatment.
However, since disease progression was observed, the
treatment with sorafenib was restarted in accordance
with the patient’s wishes.
This case shows long-term survival with use of sorafe-
nib monotherapy. Several biomarkers have been studied
as potential predictors of sorafenib response to improve
patient selection. Kusuda et al. suggested that overex-
pression of PDGFR-α might be associated with resist-
ance to sorafenib [16]. Jonasch et al. demonstrated that
a high level of phosphorylated Akt was correlated with
Fig. 1 a Computed tomographic scan taken before initiation of treatment with sorafenib reveals multiple pulmonary metastatic lesions (arrows).
b Computed tomographic scan obtained 1 year after initiation of sorafenib reveals tumor regression (arrows) of 70.1 % according to Response
Evaluation Criteria in Solid Tumors. c Computed tomographic scan taken 8 months after sorafenib therapy was stopped reveals progression of
pulmonary metastases (arrows). d Pulmonary metastases (arrows) remained stable 11 years after initiation of treatment with sorafenib
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inferior PFS and OS in patients treated with sorafenib
[17]. In addition, Aziz et al. showed that microvessel
area size was a predictor of sorafenib response [18].
These biomarkers were not examined in our patient. The
utility of molecular biomarkers for predicting clinical out-
comes with sorafenib therapy needs to be further studied.
About 3 months after starting and resuming sorafenib
therapy, our patient experienced grade 2 fatigue. Also,
myocardial infarction occurred twice during treatment
with sorafenib. Previous reports suggest that cardiotoxi-
city is a rare adverse event in patients receiving sorafenib
therapy [3, 19]. Schmidinger et al. showed that 2.9 % of
patients treated with sorafenib experienced treatment-
related fatal myocardial infarctions [20]. These events
were controlled by dose reduction or discontinuation of
sorafenib and symptomatic treatment by cardiologists.
As there is the potential for occurrence of occlusion cor-
onary artery disease during sorafenib treatment, patients
should be carefully monitored for development of symp-
toms of cardiac infarction.
There is a question whether long-term treatment with
molecular targeted agents increases the incidence of
treatment-related adverse events. There are published
data analyses of the long-term tolerability of sorafenib in
clinical settings. In the phase III study of sorafenib, long-
term treatment over approximately 3 years did not in-
crease the overall incidence of treatment-related adverse
events [21]. Furthermore, Porta et al. showed that long-
term treatment with sunitinib did not increase new or
more severe treatment-related toxicity [22]. They de-
scribed how these agents could continue to have clinical
benefit without untoward additional risk.
Currently, sequential treatment is strongly recommended
for the management of metastatic RCC when disease pro-
gression or severe adverse events emerge. Guerin et al. re-
ported a case of a patient with metastatic RCC of 14 years’
duration who had a long-term response similar to our pa-
tient’s following intermittent therapy with sorafenib [23].
Some researchers have also demonstrated that rechallenge
with the same TKI could achieve a tumor response. Some
patients with metastatic RCC retain sensitivity to mono-
therapy [24, 25]. Our present case report suggests that the
possible response to sorafenib might be maintained for a
long time in a sorafenib responder. In patients with meta-
static RCC achieving a continuous response, it is important
to continue first-line treatment including sorafenib as long
as possible by managing adverse events.
Conclusions
We present a case of a patient with metastatic RCC with
survival for over 10 years with use of sorafenib mono-
therapy. Biological predictive markers able to identify
patients who can sustain durable stabilization of disease
are desirable.
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